RxDoctor Payments Data

Reezwana Chowdhury, MD

Gastroenterology · Bethesda, MDNPI 1316185341

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Celltrion USA Inc. accounts for 73.2% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $27,912, more than ten times the $1,034 reported in 2019. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,288in general payments, 2019–2025

Across 608 payments — averaging $66.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Celltrion USA Inc.$29K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Bristol Myers Squibb$1K
  • Pfizer$607
  • plus $4K from 29 others
$41,080in research payments, 2019–2025

Across 4 payments — averaging $10,270 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ferring Pharmaceuticals AS$41K

What the payments were for

  • Consulting fees$7,74319%
  • Speaking & faculty fees$18,76447%
  • Travel & lodging$1,4634%
  • Food & beverage$12,22030%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,288 in reported general payments places this provider in the 90th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$145,720
Medicare patients
246
Services billed
5,981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine16$12,729
Famotidine16$256
Omeprazole19$210

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →